Sonoma Biotherapeutics

Clinical trials are research studies that are designed to determine if a therapy is safe and effective for patients.

The company aims to cure autoimmune disease by restoring balance to the immune system.

The company says its initial focus is on a few disease states.

The company aims to cure autoimmune disease and change the lives of patients with these diseases.

Type 1 diabetes is an autoimmune disease in which T cells destroy insulin-producing pancreatic β cells. Genetic and environmental factors increase risk by compromising immune homeostasis, and insulin therapy does not change the underlying disease or fully prevent complications.

The page covers media coverage of the company's work in cell therapy.

The page lists recent announcements about Sonoma Bio’s work.

Sonoma Biotherapeutics announced that the FDA cleared an IND application to begin a Phase 1 study of SBT115301 in healthy participants. SBT115301 is a biologic designed to eliminate highly activated effector T cells that are dominant in autoimmune and inflammatory disease.

Sonoma Biotherapeutics, Inc. today announced the appointment of Jessica Stitt as Chief Financial Officer.

The company's approach to treating and possibly curing autoimmune and inflammatory disease is similar to its approach to creating a healthy work environment.

Sonoma Bio’s board brings a diversity of experience and perspectives.

Sonoma Bio’s scientific advisory board is chaired by Fred Ramsdell, Chief Scientific Officer and co-founder of Sonoma Biotherapeutics, and includes Sonoma Bio co-founders Alexander Rudensky and Qizhi Tang.

Sonoma Bio’s four founders have worked together for years and have experience in microbiology, immunology, and research.

The story of the founding of Sonoma Bio is rooted in creating connections between disparate people and approaches—then building upon them to work better, smarter, and to do things that have never been done before.

Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system.

The company says restoring balance to the immune system could unlock cures and is advancing the application of decades of research.

The page invites inquiries about investment opportunities.

The page invites scientific inquiries.

The company accepts inquiries about partnering.

Developing living cell therapies designed to restore balance to the immune system and ultimately cure autoimmune and inflammatory disease.

Sonoma Biotherapeutics, Inc. and its affiliates collect, use, share, and safeguard personal information. The privacy policy describes individuals’ rights and choices regarding this processing.

The terms apply to content, materials, services, software, tools, and information on Sonoma Biotherapeutics’ websites and mobile applications. The sites are operated by Sonoma Biotherapeutics, Inc.